To view the PDF file, sign up for a MySharenet subscription.

DSY - Discovery Holdings Limited - Unaudited interim results and cash dividend

Release Date: 22/02/2011 10:00
Code(s): DSY
Wrap Text

DSY - Discovery Holdings Limited - Unaudited interim results and cash dividend declaration for the six months ended 31 December 2010 DISCOVERY HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (Registration number: 1999/007789/06) ISIN: ZAE000022331 Share Code: DSY UNAUDITED INTERIM RESULTS AND CASH DIVIDEND DECLARATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2010 Highlights Normalised headline earnings increase to R941 million up 25% Normalised profit from operations increase to R1 332 million up 28% New business API R3 747 million up 15% Interim dividend 42 cents per share up 27% Introduction Discovery posted strong results for the six-month period to 31 December 2010. While the period under review was complex, impacted by both the financial crisis and the considerable policy debates that affect the markets in which Discovery operates, the performance across Discovery`s businesses was pleasing. Notably, during this period, the South African economy started to stabilise and consumer confidence increased. Discovery is strongly of the view that South Africa has made considerable progress on a number of important fronts and remains excited and optimistic about the country`s future. Discovery continues to be focused on playing a positive leadership role in South Africa. Over the last 12 months, and particularly during the six-month period under review, Discovery focused on achieving growth in three key strategic areas: 1. In Discovery`s South African businesses, quality, growth and innovation were the important areas of focus. In the context of Discovery Health, this enabled us to balance the natural tension that exists between offering access to best quality care and affordable premiums, and ensuring sustainable growth. For Discovery Life, this manifested in a significant reduction in lapse rates and superior mortality and morbidity experience. Vitality experienced significant increases in levels of engagement, thereby further entrenching Vitality`s role as a differentiator through its integration capability and ability to improve mortality and morbidity experience. Discovery Invest continued to strengthen its position in the retail investment space with new product designs and platforms. 2. In Discovery`s international businesses, a step-change in strategy was employed to achieve scale, profitability and relevance - with a focus on leveraging Discovery`s unique intellectual property and capabilities to organically build businesses with minimal exposure to capital downside. In particular, the acquisition of Standard Life Healthcare, the significant work done within PruHealth and the continued successful roll-out of PruProtect, have created a business of significant size and potential in the United Kingdom. Furthermore, the important transaction concluded with Humana Inc. (Humana) in the United States and the acquisition of 20% of Ping An Health in China, provide considerable upside potential without significant capital risk. 3. A continued focus on building new businesses based on the unique business model of Discovery in the South African market. The results of these strategies were pleasing: - Normalised operating earnings, excluding the once-off effects of the Standard Life Healthcare acquisition, increased by 28% from R1 044 million to R1 332 million. - Total new business production increased by 15% from R3 246 million to R3 747 million and the embedded value increased by 15% from R21 billion to R24 billion. - Notably, focus on all aspects of the Group`s quality was reflected in strong, positive non-economic experience variances. Discovery Health Discovery Health`s performance exceeded expectation. Despite the previous period`s high base, new business grew strongly by 10% and operating profits increased by 12% from R555 million to R619 million. The total medical scheme membership managed by Discovery Health increased by 12% to 2.5 million lives. Discovery Health operates in a unique and complex environment in which clinical, actuarial, technological and regulatory factors coalesce. It is Discovery Health`s role to navigate these complexities and ensure access to quality healthcare on a sustainable basis. To achieve this during the period under review, continued focus was applied by Discovery Health to developing benefit plans, provider networks, healthcare management capabilities, and technological platforms that improve the journey of its medical scheme members under management in the healthcare system. The results were positive: the Discovery Health Medical Scheme, the largest open medical scheme in South Africa, posted the lowest contribution rate increase among major medical schemes and grew membership by 10%; lapses reduced to the lowest levels yet experienced; and importantly, almost 98% of members maintained or increased their benefit choices with only 2% buying down benefits in 2011. A fundamental goal of Discovery Health is to improve access to private healthcare for the low-income sector of the population and the progress made was excellent. Membership of the Discovery Health Medical Scheme`s plan series for this market, KeyCare, grew by 34% to 340 000. As at December 2010, the scale of KeyCare was equivalent to the third largest medical scheme in the country. During the period, Discovery Health also achieved considerable success with products designed to close gaps in healthcare coverage. For example, significant take-up was achieved by the Medical Savings Booster, which enables members to channel discounts on HealthyFoodTrade Mark purchases at Pick n Pay towards funding gaps in cover. In addition, a number of important innovations were rolled out that are aimed at reducing the cost of care and member out-of-pocket exposure and improving both the quality of care and the member`s experience in the healthcare system. To facilitate this, significant investment was made in Discovery Health`s technology platforms and risk management assets, such as electronic patient records and the development of a coordinated care model to manage complex cases. Discovery MedXpress is also being rolled out so that medical scheme members can enjoy the benefit of direct, same-day delivery of medicine, while enabling Discovery Health to manage formularies and quality of compliance. The combination of these initiatives enables Discovery Health to offer members lower price points per unit of benefit chosen. Discovery Health is determined to improve the quality of the South African healthcare system for all South Africans. In this regard, Discovery Health is committed to contribute to the successful implementation of a National Health Insurance system for South Africa, while also ensuring the sustainability and strength of the private healthcare sector as an integral part of the overall national healthcare system. Discovery Life Discovery Life`s performance was pleasing, with operating profit growing by 14% from R675 million to R768 million, new business increasing by 6% from R782 million to R832 million and the value of in-force business increasing by 14% from R8.4 billion to R9.6 billion. Notably, the positive non-economic experience variances in the embedded value illustrate the quality of the business being transacted and how it is being managed. As stated, considerable focus was applied to the quality of the business, specifically new business, lapse rates, mortality and morbidity experience, as well as capital utilisation and return on capital: 1. In the context of new business, exposure to categories that have historically generated high levels of lapses was reduced, such as the curbing of internal replacements and the re-pricing of business assurance. The effect of this was to increase the quality of new business but moderate its growth. Notably, adjusting for the impact of these categories resulted in new business growth on a like-for-like basis of 16%. 2. Discovery Life recorded a significant reduction in policy lapses to below the embedded value assumptions set for 2011. This has been an important strategy given the industry`s escalated levels of lapses during the economic slow-down. The strategies employed have illustrated the importance of Discovery`s integrated model and the benefits of policyholders` engagement in Vitality, with significantly lower levels of lapses being observed for engaged policyholders compared to policyholders who are not engaged. 3. The mortality and morbidity levels were better than expected, illustrating the quality of the business model. Importantly, the benefits of Discovery`s integrated product strategy appear to be having a positive effect on selective lapsation - the mortality and morbidity experience has been improving with policy duration and is an important factor in the sustainability and profitability of the business going forward. 4. Continued focus was applied to the company`s business model to ensure capital efficiency. As stated at the previous announcement, a unique model utilising Discovery Life`s negative Rand reserve as an asset to back capital bonds sold by Discovery Invest, has proved to be particularly successful. In addition to this, other areas of capital efficiency were achieved. Going forward, it is expected that the company`s capital requirements will be reduced by R3 billion. The combination of these initiatives will be to increase the return on capital of the business by 3% to 5%. Discovery Invest Discovery Invest`s performance exceeded expectation in all respects, with strong new business growth and mix as well as fund performance driving profitability. New business increased from R334 million to R397 million and for the period under review, operating profit of R44 million was generated compared to the operating loss of R24 million during the comparative period. Discovery Invest`s strategy has been to focus on the retail long-term savings market and to provide unique added value to consumers investing in an open architecture environment that offers investors considerable choice and investment performance. During the period under review, this strategy was maintained through, for example, the development of the Guaranteed Escalator Annuity and the Classic Flexible Investment Plan - both product constructs aimed at providing unique types and levels of protection to customers: - The Guaranteed Escalator Annuity allows investors to access the benefits of an equity-linked annuity such as fund choice flexibility, flexible withdrawal rates and capital transfer on death, with the added features of a fixed annuity, which provides guaranteed levels of income and longevity protection. - The Classic Flexible Investment Plan offers investors access to the traditional Linked Investment Service Provider (LISP) platform with over 170 funds, but with protection against poor fund performance, inappropriate performance fees, mortality protection and protection against capital gains tax liability. These products provide enhanced exposure to the two biggest retail market segments for Discovery Invest. The excellent investment performance achieved by the Discovery Invest funds was also noteworthy, with the Discovery Equity Fund and the Discovery Flexible Property Fund ranking top of their sectors since inception, and Discovery Invest`s Property Fund winning the Raging Bull Award. The combination of these factors drove growth in assets under management, with 87% of fund choices allocated to Discovery Funds, an important factor in driving profit margins. It is anticipated that Discovery Invest will continue to grow in scale, quality and profitability. Vitality Vitality`s performance was exceptional and its role in product integration, engagement and achieving superior levels of mortality and morbidity experience accelerated during the period under review. Engagement levels of key Vitality benefits increased dramatically with gym membership rising by 20% from 296 116 to 356 533; HealthyFoodTrade Mark activations exceeding 228 000; and levels of engagement across all Vitality categories increasing. Vitality has continued its work in understanding the link between engagement with Vitality and mortality and morbidity experience from an academic perspective, and the link between different incentive types and the effect of complex and simple behaviours to establish positive health behaviour. It is this significant knowledge and capability that has been used to underpin both Discovery`s local and international businesses. The DiscoveryCard performed particularly well during the period under review and reflected both the quality of Discovery`s client base and the improving economic environment. The DiscoveryCard captured 8% of the point-of-sale market share and the quality of the credit experience remained above expectation. Today, Discovery members spend almost R1 billion per month on their DiscoveryCards. An exciting advancement during the period was the development of the Discovery Purple Card aimed at providing the higher-end market segment with unique value. PruHealth A change in strategy to achieve scale, relevance and profitability for PruHealth, delivered positive results during the period under review. Firstly, the acquisition of Standard Life Healthcare accelerated Discovery`s strategy in the United Kingdom, with the transaction providing immediate scale in the Private Medical Insurance market, as well as the opportunity for Discovery to increase its shareholding in both PruHealth and PruProtect, from 50% to 75%. As part of the Standard Life Healthcare acquisition, Discovery secured long- term access to Prudential plc`s brand and life fund in the United Kingdom, which is important to the competitive position of both PruHealth and PruProtect. Secondly, considerable work was undertaken to manage the key value drivers of the PruHealth standalone business, with activity intensifying over the past six months. The combination of these initiatives resulted in an operating profit of R35 million (100% of income), versus a loss of R53 million (50% of loss) during the comparative period. New business increased by 90% from R165 million to R313 million, and removing the effects of the Standard Life Healthcare new business, PruHealth`s new business increased by 35%. Importantly, PruHealth`s combined Vitality and claims loss ratio reduced by 15%, while expense per policy reduced by 27% on a calendar year basis and positive lapses and selection were achieved during the period. During the period under review, delivery was taken of the Standard Life Healthcare business and the process of integrating it into the PruHealth business began. The quality of the asset acquired surpassed expectations, with the loss ratio, levels of lapsation and profitability levels exceeding expectation. The combination of the management action undertaken within PruHealth, and the acquisition of Standard Life Healthcare, has created a business with strong fundamental drivers of value and one that represents significant prospects for Discovery. Considerable research and development was also undertaken to develop a unified product range that reflects the unique strengths of both businesses. This product range was launched during February 2011 and incorporated the modularity of Standard Life Healthcare`s previous product range with the Vitality integration capability of PruHealth. PruHealth remains confident in its ability to transact increased levels of profitable new business via the new product range. PruProtect PruProtect delivered an excellent operating performance with strong growth in both new business and earnings, and industry recognition of its differentiated product offerings. New business grew by 44% from R100 million to R144 million and operating losses narrowed to R40 million (100%). PruProtect`s strategy is to build a significant life insurance company on a similar basis to that of the Discovery Life model to provide unique value to customers in the United Kingdom. Given the complexity of the market and its capital intensity, it is imperative that the business is built on the basis of quality. In this regard, PruProtect exceeded expectations: lapses were lower than expected, mortality and morbidity experience were better than expected, and the product mix was acceptable. Additionally, given the business`s increasing scale, expenses per policy decreased by 57%. The offsetting of negative reserves created by PruProtect against positive reserves within Prudential plc`s life fund has enabled PruProtect to achieve scale on a relatively light capital basis. The combination of this and the strong underlying performance has created a business that is expected to achieve superior returns on capital. During the period under review, PruProtect concentrated on strengthening and increasing the breadth of the Independent Financial Advisers distribution channel through PruProtect`s franchises. From a product perspective, PruProtect was once again recognised as the leading protection provider in the United Kingdom, further winning industry awards for its innovative critical illness and income protection cover. In addition, work was done on a number of different product offerings that will be rolled out during March 2011. The Vitality Group Over the last few years, Discovery has maintained a small presence in the United States via The Vitality Group that develops and markets Vitality to large employers and health carriers. Given the uniqueness and potential of Vitality, the importance of wellness in a post healthcare-reform environment in the United States, and Discovery`s considerable Vitality capabilities, a decision was made to accelerate The Vitality Group`s development dramatically. This included the expansion of the wellness and reward network, and refinement of the clinical and actuarial pathways supporting the programme. Despite a relatively insignificant distribution capability, The Vitality Group membership grew to 140 000 members by the end of 2010. Importantly, the structure of the business minimises Discovery`s exposure to capital and earnings risk. To up-scale the business and capitalise on emerging opportunities, Discovery concluded a transaction with Humana, the fourth largest health insurer in the United States covering 18 million members (comprising 10.2 million medical members and 7.1 million ancillary product members). Under the terms of the transaction, Humana will capitalise a new entity, US-based Humana-Vitality, in which Discovery will hold a 25% stake. Humana- Vitality will provide Humana members with access to the Vitality programme, which will be tailored to Humana`s product range and markets. Furthermore, Humana will acquire a 25% stake in The Vitality Group. The transaction will result in Discovery being able to leverage its unique consumer-engaged and integrated health-and-wellness model in the United States health insurance market with little capital and no insurance risk, while retaining The Vitality Group`s autonomy to pursue the self-insured employer wellness market. The greater scale and capital afforded by this structure will allow The Vitality Group and Humana-Vitality to considerably enhance the existing wellness networks and platforms in the United States. During the period under review, work was also done to operationalise the partnership with Wellness and Prevention Inc. (a Johnson & Johnson company), in preparation for the 2011 quarter one launch. Ping An Health Over the past six months, significant work has taken place to operationalise Ping An Health, the joint venture between Discovery and the Ping An Group of China, the world`s second-largest insurance company. During the period under review, the necessary regulatory approvals were received from the Chinese Insurance Regulatory Commission. Operationally, the process of transferring the necessary product and system capabilities to Ping An Health began, with the Discovery team deployed successfully. From a product perspective, significant work has taken place to tailor the Discovery capabilities to the Chinese market and we remain excited by the potential of the Chinese private health insurance market in the long-term. MI Hilkowitz A Gore Chairperson Chief Executive Officer Income statement for the six months ended 31 December 2010 R million Group Group % Group Six Six change Year months months ended ended ended June December December 2010
2010 2009 Audited Unaudited Unaudited Insurance premium revenue 5 988 3 278 83 7 860 Premium revenue from - 1 865 1 865 investment contracts transferred to insurance contracts Reinsurance premiums (816) (592) (1 172) Net insurance premium 5 172 4 551 8 553 revenue Fee income from 1 881 1 592 18 3 380 administration business Investment income 108 106 239 Net realised gains on 192 86 123 200 available-for-sale financial assets Net fair value gains on 702 326 276 financial assets at fair value through profit or loss Vitality income 685 525 30 1 182 Net income 8 740 7 186 13 830 Claims and policyholders` (2 594) (1 194) (2 586) benefits Insurance claims 573 393 841 recovered from reinsurers Recapture of reinsurance (312) - - Net claims and (2 333) (801) (191) (1 745) policyholders` benefits Acquisition costs (1 192) (1 112) (7) (1 961) Marketing and (2 941) (2 252) (31) (4 813) administration expenses Amortisation of (44) - - intangibles from business combinations Recovery of expenses from 79 74 95 reinsurers Transfer from (966) (1 692) (2 717) assets/liabilities under insurance contracts - change in assets 924 744 1 639 arising from insurance contracts - change in liabilities (1 802) (2 436) (4 291) arising from insurance contracts - change in liabilities (88) - (65) arising from reinsurance contracts Fair value adjustment to (99) (219) (175) liabilities under investment contracts Profit from operations 1 244 1 184 2 514 Gains and losses 609 - - resulting from business combinations Write-off of software (95) - - from business combination Finance costs (38) (5) (14) Foreign exchange loss (22) (6) (3) Profit before tax 1 698 1 173 45 2 497 Income tax expense (390) (346) (782) Profit for the period 1 308 827 58 1 715 Profit attributable to: - equity holders 1 417 829 1 717 - non-controlling (109) (2) (2) interest 1 308 827 1 715
Earnings per share for profit attributable to the equity holders of the company during the period (cents): - basic 255.6 149.6 71 309.9 - diluted 255.4 149.1 71 308.7 Statement of comprehensive income for the six months ended 31 December 2010 R million Group Group % Group Six Six change Year months months ended
ended ended June December December 2010 2010 2009 Audited Unaudited Unaudited
Profit for the period 1 308 827 58 1 715 Other comprehensive income: Change in available-for- (79) 188 33 sale financial assets - unrealised gains 92 305 238 - capital gains tax on (6) (43) (33) unrealised gains - realised gains (192) (86) (200) transferred to income - capital gains tax on 27 12 28 realised gains Currency translation (346) (19) (20) differences - increase in currency (365) (19) (20) translation reserve - transfer to profit or 19 - - loss on disposal of joint venture Cash flow hedges (10) (18) 12 - realised (gains)/losses (2) (30) 2 transferred to income - tax on realised * (1) * gains/losses - unrealised (17) 16 22 gains/(losses) - tax on unrealised 9 (3) (12) gains/losses Other comprehensive (435) 151 25 income for the period, net of tax Total comprehensive 873 978 (11) 1 740 income for the period Attributable to: - equity holders 982 980 1 742 - non-controlling (109) (2) (2) interest Total comprehensive 873 978 1 740 income for the period * Amount is less than R500 000. Headline earnings for the six months ended 31 December 2010 R million Group Group % Group Six Six change Year
months months ended ended ended June December December 2010 2010 2009 Audited
Unaudited Unaudited Normalised headline earnings per share (cents): - undiluted 169.6 136.4 24 278.8 - diluted 169.5 135.9 25 277.7 Headline earnings per share (cents): - undiluted 114.7 136.4 (16) 278.8 - diluted 114.6 135.9 (16) 277.7 The reconciliation between earnings and headline earnings is shown below: Net profit attributable 1 417 829 1 717 to equity shareholders Adjusted for: - realised gains on (165) (74) (172) available-for-sale financial instruments net of CGT - gain on disposal of (667) - - joint venture - write-off of software 51 - - from business combination net of deferred tax* Headline earnings 636 755 (16) 1 545 - recapture of 234 - - reinsurance* - amortisation of 24 - - intangibles from business combinations* - once-off costs relating 47 - - to acquisitions* Normalised headline 941 755 25 1 545 earnings * Amounts shown at 75% less any related tax Weighted number of shares 554 485 553 796 554 117 in issue (000`s) Diluted weighted number 554 793 555 733 556 257 of shares (000`s) Segmental information for the six months ended 31 December 2010 R million SA SA Life SA SA UK Health Invest Vitalit Health y 31 December 2010 Income statement Insurance premium revenue 12 2 461 1 659 - 1 733 Reinsurance premiums (1) (481) - - (298) Net insurance premium 11 1 980 1 659 - 1 435 revenue Fee income from 1 668 61 105 28 6 administration business Investment income 11 68 2 5 5 Inter-segment funding - (100) 100 - - Net realised gains on - 193 - - (1) available-for-sale financial assets Net fair value gains on - 247 455 - - financial assets at fair value through profit or loss Vitality income - - - 629 37 Net income 1 690 2 449 2 321 662 1 482 Claims and policyholders` (6) (1 (262) - (1 benefits 078) 217) Insurance claims - 333 - - 226 recovered from reinsurers Net claims and (6) (745) (262) - (991) policyholders` benefits Acquisition costs - (715) (154) (28) (128) Marketing and administration expenses - depreciation and (69) (12) (5) - (2) amortisation - other expenses (985) (479) (100) (628) (406) Recovery of expenses from - - - - 79 reinsurers Transfer from assets/liabilities under insurance contracts - change in assets - 727 - - (4) arising from insurance contracts - change in liabilities - (96) (1 - 9 arising from insurance 716) contracts - change in liabilities - (71) - - - arising from reinsurance contracts Fair value adjustment to - (61) (38) - - liabilities under investment contracts Profit/(loss) from 630 997 46 6 39 operations Recapture of reinsurance - - - - - Gains and losses - - - - - resulting from business combinations Amortisation of - - - - - intangibles from business combinations Write-off of software - - - - - from business combination Finance costs - - - - (7) Foreign exchange loss (12) (6) (3) - - Profit/(loss) before tax 618 991 43 6 32 Income tax expense (166) (246) (12) (1) 6 Profit/(loss) for the 452 745 31 5 38 period Attributable to: - equity holders 452 745 31 5 13 - non-controlling - - - - 25 interest 452 745 31 5 38 31 December 2009 Income statement Insurance premium revenue 13 2 076 833 - 321 Premium revenue from - - 1 865 - - investment contracts transferred to insurance contracts Reinsurance premiums (1) (448) - - (132) Net insurance premium 12 1 628 2 698 - 189 revenue Fee income from 1 469 46 50 20 1 administration business Investment income 13 45 32 9 - Net realised gains on - 86 - - - available-for-sale financial assets Net fair value gains on - 132 194 - - financial assets at fair value through profit or loss Vitality income - - - 510 - Net income 1 494 1 937 2 974 539 190 Claims and policyholders` (6) (886) (34) - (237) benefits Insurance claims - 287 - - 104 recovered from reinsurers Net claims and (6) (599) (34) - (133) policyholders` benefits Acquisition costs - (660) (304) (33) (29) Marketing and administration expenses -'depreciation and (62) (7) (4) - - amortisation -'other expenses (858) (457) (82) (480) (149) Recovery of expenses from - - - - 69 reinsurers Transfer from assets/liabilities under insurance contracts -'change in assets - 674 (2) - - arising from insurance contracts -'change in liabilities - (47) (2 - (1) arising from insurance 406) contracts -'change in liabilities - (2) - - - arising from reinsurance contracts Fair value adjustment to - (57) (162) - - liabilities under investment contracts Profit/(loss) from 568 782 (20) 26 (53) operations Finance costs - - - - - Foreign exchange loss (4) (2) - - - Profit/(loss) before tax 564 780 (20) 26 (53) Income tax expense (159) (198) 6 (3) 9 Profit/(loss) for the 405 582 (14) 23 (44) period Attributable to: -'equity holders 405 582 (14) 23 (44) -'non-controlling - - - - - interest 405 582 (14) 23 (44) Segmental information for the six months ended 31 December 2010 R million UK Life USA New All Total Health busines other s seg- Develop- ments*
ment 31 December 2010 Income statement Insurance premium revenue 123 - - - 5 988 Reinsurance premiums (36) - - - (816) Net insurance premium 87 - - - 5 172 revenue Fee income from 9 - - 4 1 881 administration business Investment income 2 - - 15 108 Inter-segment funding - - - - - Net realised gains on - - - - 192 available-for-sale financial assets Net fair value gains on - - - - 702 financial assets at fair value through profit or loss Vitality income - - 19 - 685 Net income 98 - 19 19 8 740 Claims and policyholders` (32) 1 - - (2 benefits 594) Insurance claims 14 - - - 573 recovered from reinsurers Net claims and (18) 1 - - (2 policyholders` benefits 021) Acquisition costs (167) - - - (1 192)
Marketing and administration expenses -'depreciation and - - (2) - (90) amortisation -'other expenses (135) (12) (90) (16) (2 851) Recovery of expenses from - - - - 79 reinsurers Transfer from assets/liabilities under insurance contracts -'change in assets 201 - - - 924 arising from insurance contracts -'change in liabilities - 1 - - (1 arising from insurance 802) contracts -'change in liabilities (17) - - - (88) arising from reinsurance contracts Fair value adjustment to - - - - (99) liabilities under investment contracts Profit/(loss) from (38) (10) (73) 3 1 600 operations Recapture of reinsurance - - - (312) (312) Gains and losses - - - 609 609 resulting from business combinations Amortisation of - - - (44) (44) intangibles from business combinations Write-off of software - - - (95) (95) from business combination Finance costs (12) - - (19) (38) Foreign exchange loss - - - (1) (22) Profit/(loss) before tax (50) (10) (73) 141 1 698 Income tax expense 16 - - 13 (390) Profit/(loss) for the (34) (10) (73) 154 1 308 period Attributable to: - equity holders (25) (10) (72) 278 1 417 - non-controlling (9) - (1) (124) (109) interest (34) (10) (73) 154 1 308 31 December 2009 Income statement Insurance premium revenue 34 1 - - 3 278 Premium revenue from - - - - 1 865 investment contracts transferred to insurance contracts Reinsurance premiums (11) - - - (592) Net insurance premium 23 1 - - 4 551 revenue Fee income from - - - 6 1 592 administration business Investment income - - - 7 106 Net realised gains on - - - - 86 available-for-sale financial assets Net fair value gains on - - - - 326 financial assets at fair value through profit or loss Vitality income - - 15 - 525 Net income 23 1 15 13 7 186 Claims and policyholders` (4) (27) - - (1 benefits 194) Insurance claims 1 1 - - 393 recovered from reinsurers Net claims and (3) (26) - - (801) policyholders` benefits Acquisition costs (77) - (9) - (1 112) Marketing and administration expenses - depreciation and - - (2) - (75) amortisation - other expenses (61) (15) (66) (9) (2 177) Recovery of expenses from reinsurers 5 - - - 74 Transfer from assets/liabilities under insurance contracts - change in assets 72 - - - 744 arising from insurance contracts - change in liabilities - 18 - - (2 arising from insurance 436) contracts - change in liabilities 2 - - - - arising from reinsurance contracts Fair value adjustment to - - - - (219) liabilities under investment contracts Profit/(loss) from (39) (22) (62) 4 1 184 operations Finance costs - (1) - (4) (5) Foreign exchange loss - - - - (6) Profit/(loss) before tax (39) (23) (62) - 1 173 Income tax expense 16 - 4 (21) (346) Profit/(loss) for the (23) (23) (58) (21) 827 period Attributable to: - equity holders (23) (23) (56) (21) 829 - non-controlling - - (2) - (2) interest (23) (23) (58) (21) 827 * All other segments include the impacts from business combinations. Statement of financial position at 31 December 2010 R million Group Group December June
2010 2010 Unaudited Audited ASSETS Assets arising from insurance contracts 8 174 7 076 Property and equipment 206 220 Investment property 19 19 Intangible assets including deferred 1 492 325 acquisition costs Goodwill 1 068 - Financial assets - Equity securities 2 939 2 892 - Equity linked notes 3 954 2 861 - Debt securities 1 293 714 - Inflation linked securities 80 68 - Money market 3 123 1 453 - Derivatives 74 111 - Loans and receivables including insurance 2 058 1 885 receivables Deferred income tax 174 303 Current income tax asset 20 101 Reinsurance contracts 183 121 Cash and cash equivalents 1 896 2 845 Total assets 26 753 20 994 EQUITY Capital and reserves Share capital and share premium 1 558 1 541 Other reserves 140 574 Retained earnings 7 470 6 267 9 168 8 382 Non-controlling interest 785 - Total equity 9 953 8 382 LIABILITIES Liabilities arising from insurance contracts 8 938 6 198 Liabilities arising from reinsurance contracts 1 286 1 160 Financial liabilities - Investment contracts at fair value through 1 893 1 544 profit or loss - Borrowings at amortised cost 402 23 - Derivatives 14 12 Deferred income tax 2 199 1 849 Deferred revenue 47 75 Employee benefits 73 70 Trade and other payables 1 948 1 681 Total liabilities 16 800 12 612 Total equity and liabilities 26 753 20 994 Statement of changes in equity for the six months ended 31 December 2010 Attributable to equity holders of the Company
Share Share- Revalu Trans- Hedgin Re- Total capita based a- lation g tained l paymen tion reserv Re- Earn- and t re- e serve ings
share re- serve* premiu serve m
R million Period ended 31 December 2010 At beginning 1 541 316 145 76 37 6 267 8 382 of period Profit for - - - - - 1 417 1 417 the period Other - - (79) (346) (10) - (435) comprehensive income Total - - (79) (346) (10) 1 417 982 comprehensive income for the period Transactions with owners: Non- - - - - - - - controlling interest shares issues Realised 17 - - - - - 17 gains from treasury shares Employee share option schemes: - Value of - 1 - - - - 1 employee services Dividends - - - - - (214) (214) paid to equity holders Total 17 1 - - - (214) (196) transactions with owners At end of 1 558 317 66 (270) 27 7 470 9 168 period Period ended 31 December 2009 At beginning 1 548 307 112 96 25 4 925 7 013 of period Profit for - - - - - 829 829 the period Other - - 188 (19) (18) - 151 comprehensive income Total - - 188 (19) (18) 829 980 comprehensive income for the period Transactions - - - - - - - with owners: Non- controlling interest shares issue Realised 5 - - - - - 5 gains from treasury shares Employee share option schemes: - Value of - 4 - - - - 4 employee services Dividends - - - - - (194) (194) paid to equity holders Total 5 4 - - - (194) (185) transactions with owners At end of 1 553 311 300 77 7 5 560 7 808 period * This reserve relates to the revaluation of available-for-sale financial assets. Statement of changes in equity for the six months ended 31 December 2010 R million Non- Total con- trollin g
interes t Period ended 31 December 2010 At beginning of period - 8 382 Profit for the period (109) 1 308 Other comprehensive income - (435) Total comprehensive income for the period (109) 873 Transactions with owners: Non-controlling interest shares issues 894 894 Realised gains from treasury shares - 17 Employee share option schemes: - Value of employee services - 1 Dividends paid to equity holders - (214) Total transactions with owners 894 698 At end of period 785 9 953 Period ended 31 December 2009 At beginning of period - 7 013 Profit for the period (2) 827 Other comprehensive income - 151 Total comprehensive income for the period (2) 978 Transactions with owners: 2 2 Non-controlling interest shares issue Realised gains from treasury shares - 5 Employee share option schemes: - Value of employee services - 4 Dividends paid to equity holders - (194) Total transactions with owners 2 (183) At end of period - 7 808 Statement of cash flows for the six months ended 31 December 2010 R million Group Group Group Six Six Year
months months ended ended ended June December December 2010 2010 2009 Audited
Unaudited Unaudited Cash flow from operating activities (824) 1 066 1 630 Cash generated by operations 1 561 2 229 4 472 Policyholder net investments (2 048) (1 240) (2 988) Working capital changes (473) 179 330 (960) 1 168 1 814 Dividends received 33 17 31 Interest received 143 96 226 Interest paid (28) (5) (14) Taxation paid (12) (210) (427) Cash flow from investing activities (340) (343) (105) Net disposals/(purchases) of 802 (183) 112 financial assets Net purchases of equipment (17) (108) (127) Purchase of intangible assets (53) (52) (90) Purchase of subsidiary (1 072) - - Cash flow from financing activities 279 (199) (396) Proceeds from issuance of ordinary 106 2 2 shares Dividends paid to equity holders (214) (194) (389) Repayment of borrowings (13) (7) (9) Increase in borrowings 400 - - Net increase in cash and cash (885) 524 1 129 equivalents Cash and cash equivalents at 2 845 1 737 1 737 beginning of year Exchange losses on cash and cash (64) (21) (21) equivalents Cash and cash equivalents at end of 1 896 2 240 2 845 period Review of Group results Value creators New business annualised premium income increased 15% for the six months ended 31 December 2010. New business annualised premium income R million December December % change 2010 2009 Discovery Health 1 974 1 787 10 Discovery Life 832 782 6 Discovery Invest 397 334 19 Discovery Vitality 87 78 12 PruHealth 313 165 90 PruProtect 144 100 44 New business API of Group 3 747 3 246 15 New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single premium policies. It also includes both automatic premium increases and servicing increases on existing policies. Gross inflows under management increased 27% for the six months ended 31 December 2010. 5% of the increase is attributable to the gross inflows from PruHealth Insurance Limited (previously Standard Life Healthcare) being included from 1 August 2010. Gross inflows under management R million December December % change 2010 2009 Discovery Health 15 115 12 758 18 Discovery Life 2 522 2 121 19 Discovery Invest 3 626 2 614 39 Discovery Vitality 676 545 24 Destiny Health - 4 PruHealth 1 829 644 184 PruProtect 142 68 109 Gross inflows under management 23 910 18 754 27 Less: collected on behalf of third (15 356) (13 359) (15) parties Discovery Health (13 431) (11 269) (19) Discovery Invest (1 862) (1 732) (8) Destiny Health - (2) PruHealth (53) (322) 84 PruProtect (10) (34) 71 Gross income of Group 8 554 5 395 59 Gross inflows under management measures the total funds managed and received by Discovery and is an accurate measure of the continual growth of Discovery. Profit from operations The following table shows the main components of the increase in Group profit from operations for the six months ended 31 December 2010: R million December December % change 2010 2009 Discovery Health 619 555 12 Discovery Life 768 675 14 Discovery Invest 44 (24) 283 Discovery Vitality 1 17 (94) PruHealth 35 (53) 166 PruProtect (40) (39) (3) Profit from existing operations 1 427 1 131 26 Development and other segments (95) (87) (9) Normalised profit from operations 1 332 1 044 28 Recapture of reinsurance (312) - Gains and losses resulting from 609 - business combinations Write-off of software from business (95) - combination Amortisation of intangibles from (44) - business combinations Investment income attributable to 76 54 41 equity holders Net realised gains on available-for- 192 86 123 sale financial assets Finance costs and foreign exchange (60) (11) (445) loss Profit before tax 1 698 1 173 45 From 1 August 2010, PruHealth and PruProtect have been accounted for as subsidiaries in the Group results, previously accounted for as joint ventures. This means that the comparatives disclosed include the income, expenses, assets and liabilities of these companies at 50%, but at 100% in the current results, from 1 August 2010. Acquisition of Standard Life Healthcare and related capital restructure Background On 31 July 2010, Discovery acquired the entire share capital of Standard Life Healthcare ("SLHC"), a wholly-owned subsidiary of the Standard Life Group, for R1.56 billion (GBP137.8 million). Discovery`s joint venture with Prudential has created a strong foothold in both the health insurance and protection markets in the UK. The acquisition of SLHC is likely to accelerate the attainment of both PruHealth and PruProtect`s UK strategies. In health insurance, where scale is important, the acquisition created a new competitor covering approximately 700 000 lives and attracting annual premiums of R4.1 billion (GBP370 million). In addition, the acquisition will provide PruHealth with opportunities to sell Vitality into SLHC`s existing client base. In the protection market, SLHC`s large, high-quality client base provides growth opportunities for PruProtect, and enhances Discovery`s ability to implement its integrated model in the UK. Discovery funded the entire purchase consideration by using R1.16 billion from its own internal funds (dividend from Discovery Life) and through raising debt of R400 million. Discovery then contributed SLHC to PruHealth Holdings Limited ("PHHL") as a capital investment. PHHL is the holding company of PruHealth and PruProtect, the joint ventures between Discovery and Prudential Assurance Company of the United Kingdom. This resulted in Discovery increasing its interest in both PruHealth and PruProtect from 50% to 75%. Accounting for the transactions In terms of IFRS 3 revised: Business Combinations, the increase in Discovery`s interest from 50% (a joint venture) to 75% (a subsidiary) must be treated as two separate transactions, that is, the disposal of the 50% interest and a subsequent acquisition of 75% interest. The purchase price for the increased shareholding must be used to calculate the deemed disposal consideration for the disposal of the 50% interest. Any resulting profit or loss (in this case profit) must be included in the earnings of the Group but is excluded from headline earnings. Using the GBP137.8 million that Discovery invested into PHHL to increase its shareholding by 25%, the deemed disposal consideration for the 50% interest is GBP69 million. Discovery has reflected a profit of R667 million in its earnings for the period to 31 December 2010, which has been excluded from headline earnings. For the 75% deemed subsequent acquisition, IFRS 3 revised states that this should be treated as if it was an independent acquisition at that time and requires the purchase price be allocated to the tangible assets and liabilities and to the intangible assets acquired. The balance is allocated to goodwill. The purchase price for the acquisition of SLHC and the deemed purchase price for the 75% of PHHL must be allocated in this manner and the appropriate portions allocated to non-controlling interest. In addition, for this purpose, assets must be valued on an arms-length basis to third parties, and should not take into account Discovery`s intentions post the acquisition. Discovery has allocated the purchase price as follows: Allocation of the purchase price for 75% of PHHL GBP R million million*
Tangible net asset value: - Assets arising from insurance contracts 36.8 379 - Property and equipment 0.2 2 - Deferred acquisition costs 4.3 44 - Loans and receivables including insurance 52.0 535 receivables - Reinsurance assets 4.2 43 - Cash and cash equivalents 195.5 2 013 - Liabilities arising from insurance contracts (12.8) (132) - Liabilities arising from reinsurance contracts (8.6) (89) - Borrowings at amortised cost (29.7) (306) - Trade and other payables (85.8) (883) Intangible assets: - Value of in-force business 36.1 372 - Prudential brand 15.7 162 - Deferred tax liability raised in respect of (14.5) (149) intangible assets - Provisional goodwill 82.6 851 - Non-controlling interest (69.0) (711) Deemed consideration paid 207.0 2 131 Allocation of the purchase price for 100% of SLHC GBP R million million* Tangible net asset value: - Property and equipment 0.4 4 - Deferred acquisition costs 14.4 148 - Money market investments 130.7 1 346 - Loans and receivables including insurance 2.1 22 receivables - Deferred income tax 1.3 13 - Reinsurance assets 3.6 37 - Cash and cash equivalents 15.2 157 - Liabilities arising from insurance contracts (68.2) (702) - Deferred revenue (0.8) (8) - Trade and other payables (22.8) (235) Intangible assets: - Value of in-force business 48.1 495 - Software 8.6 89 - Deferred tax liability raised in respect of (15.9) (164) intangible assets - Provisional goodwill 21.1 217 Consideration paid 137.8 1 419 * Translated at closing rate at 31 December 2010, which is the rate they are included in the Statement of Financial Position. The intangible assets identified in the tables above have been included in the Statement of Financial Position of the Group. These intangible assets will be amortised over their remaining useful lives and tested for impairment at each reporting date. Discovery has recorded an amortisation charge of R44 million in profit or loss for the period 1 August 2010 to 31 December 2010 for these intangible assets. The value of in-force business, being the value for the existing customer contracts at the date of acquisition, was calculated using a discounted cash flow model which is similar to an embedded value model and is being amortised on the basis of unwinding of the modelled cash flows. The computer software acquired as part of the SLHC acquisition will not be used by Discovery and accordingly the value of GBP8.6 million (R95 million) (before taking into account the impact on non-controlling interest) has been written-off. The provisional goodwill, which represents the value of future business expected to be written by the PHHL Group, is not amortised, but is assessed for possible impairment at each reporting date and the impairment is recorded in profit or loss, if necessary. Reconciliation of goodwill GBP R million
million Provisional goodwill recognised from the 82.6 943 purchase of PHHL Provisional goodwill recognised from the 21.1 241 purchase of SLHC Net exchange difference arising during the (116) period Goodwill at 31 December 2010 103.7 1 068 In terms of IFRS 3 revised, paragraph 45, the initial accounting for an acquisition can be undertaken on a provisional basis for this reporting period. Adjustments to provisional values can be made within one year of the effective date, relating to facts or circumstances at the acquisition date. Gains and losses resulting from business combinations The following gains and losses resulting from the business combinations described above have been included in the Group`s income statement at 31 December 2010: R million Gross Tax Net Non- Attri- Con- butable trolling to equity interest holders
Gain recognised on 667 - 667 - 667 disposal of joint venture Write-off of (95) 27 (68) 17 (51) software Excluded from 572 27 599 17 616 headline earnings Amortisation of (44) 12 (32) 8 (24) intangibles Once-off costs (58) - (58) 11 (47) relating to acquisition Recapture of (312) - (312) 78 (234) reinsurance Total adjustments 158 39 197 114 311 to earnings to arrive at normalised earnings In the process of completing the acquisition, Discovery incurred once-off costs such as investment banking fees, legal costs and other consulting fees. Recapture of reinsurance The business combinations discussed above resulted in a need for Discovery to restructure the capital of PHHL and PruHealth. SLHC had surplus capital and PruHealth had reinsurance obligations, some of which was not required for the combined businesses. PruHealth therefore undertook the recapture of approximately GBP28 million of reinsurance obligations which resulted in a R312 million charge to Discovery`s income statement (before taking into account the impact on non-controlling interest). Post-acquisition revenue and profit or loss of acquired entities The table below discloses the post-acquisition revenue and profit or loss that has been included in the Group`s income statement at 31 December 2010: R million UK UK Life Health Revenue 1 723 122 Profit or loss after tax (100%) 53 (28) Revenue and profit or loss of acquired entities from 1 July 2010 The table below discloses the revenue and profit or loss that would have been included in the Group`s income statement at 31 December 2010, if the acquisition date was 1 July 2010: R million UK Health UK Life Revenue 2 072 142 Profit or loss after tax (100%) 31 (40) Other significant transactions affecting the current interim results Share-based payments Included in marketing and administration expenses is R107 million (2009: R79 million) in respect of options granted under employee share incentive schemes expensed in accordance with the requirements of IFRS 2. The Group entered into transactions to hedge its exposure in the phantom share scheme related to changes in the Discovery share price. As at 31 December 2010, approximately 67.3% (2009: 62%) of this exposure was hedged. Taxation All South African entities are in a tax paying position. South African income tax has been provided at 28% (2009: 28%) and secondary tax on companies at 10% in the financial statements and embedded value statements. Discovery obtained no tax relief for the PruHealth losses in respect of the calendar year ending 31 December 2010. Discovery obtained tax relief for half of the PruHealth losses in respect of the calendar year ending 31 December 2009, as this tax asset was ceded to Prudential Assurance Company in the UK ("Prudential"). R9 million in respect of this tax relief has been included in income tax at 31 December 2009. Tax relief is obtained for 100% of the PruProtect losses through Prudential. Significant movements in the Statement of Financial Position The increase in the assets arising from insurance contracts of R1 098 million is primarily as a result of profitable new business written by Discovery Life. Financial assets have increased due to the sale of Discovery Invest products and the inclusion of Standard Life Healthcare money market investments of R1 322 million at 31 December 2010. Whilst Discovery has made a payment of R225 million for the acquisition of 20% of Ping An Health Insurance Company of China, Limited, the acquisition has not been finally concluded. The effective date is thus post 31 December 2010. This payment has been included in equity investments in the Statement of Financial Position. Borrowings at amortised cost, includes a long-term loan of R400 million raised as part of the funding to purchase Standard Life Healthcare. Interest on the loan is payable quarterly, for which a fixed interest rate swap has been entered into. The loan is repayable on 11 September 2017. The deferred tax liability is primarily attributable to the application of the Financial Services Board directive 145. This directive allows for the zeroing on a statutory basis of the assets arising from insurance contracts. The statutory basis is used when calculating tax payable for Discovery Life, resulting in a timing difference between the tax base and the accounting base. Shareholder information Directorate There have been no changes to the directorate for the six months ended 31 December 2010. Repurchase of shares As advised in SENS announcement on 9 December 2010, Discovery has acquired and cancelled 80 790 ordinary shares from one of Discovery`s directors, Sindiswa Zilwa, through her investment vehicle, Newshelf 801 (Proprietary) Limited as one of Discovery`s BEE partners. Dividend policy and capital A final dividend of 36 cents per share was paid on 18 October 2010. The directors are of the view that the Discovery Group is adequately capitalised at this time. On the statutory basis the capital adequacy requirements of Discovery Life was R303 million (2009: R258 million) and was covered 3.9 times (2009: 8.6 times). Cash dividend declaration: The board has declared an interim dividend of 42 cents per share. The salient dates are as follows: - Last date to trade "cum" dividend Friday, 11 March 2011 - Date trading commences "ex" dividend Monday, 14 March 2011 - Record date Friday, 18 March 2011 - Date of payment Tuesday, 22 March 2011 Share certificates may not be dematerialised or rematerialised between Monday, 14 March 2011 and Friday, 18 March 2011, both days inclusive. Accounting policies The interim results have been prepared in accordance with International Financial Reporting Standards including IAS 34, as well as the South African Companies Act 61 of 1973, as amended. The accounting policies adopted are consistent with the accounting policies applied in the last annual report and the corresponding prior year period. Discovery entered into a business combination for the first time in the current reporting period. As such, IFRS 3 revised, has been adopted. Comparative figures There have been no changes to comparative figures. Embedded value statement for the six months ended 31 December 2010 The embedded value of Discovery at 31 December 2010 consists of the following components: - the free surplus attributed to the covered business at the valuation date; - plus: the required capital to support the in-force covered business at the valuation date; - plus: the present value of future shareholder cash flows from the in-force business; - less: the cost of required capital and secondary tax on companies ("STC"). The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax shareholder cash flows of the business in force at the valuation date, discounted at the risk discount rate. The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new business written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain (for Life), initial expenses, cost of capital and STC. The value of new business is calculated using the current reporting date assumptions. For Life, the shareholder cash flows are based on the release of margins under the Statutory Valuation Method ("SVM") basis. The embedded value includes the insurance and administration profits of the subsidiaries in the Discovery Holdings Group. Covered business includes business written through Discovery Life, Discovery Invest, Discovery Health, Discovery Vitality, PruHealth and Standard Life Healthcare in the United Kingdom. For The Vitality Group (USA) and PruProtect, no published value has been placed on the current in-force business. On 1 August 2010, Discovery acquired Standard Life Healthcare and increased its shareholding in the Prudential joint venture from 50% to 75%. For embedded value purposes, the value of the Standard Life Healthcare in-force business has been calculated based on the acquisition price of GBP138 million less the net asset value of the business at 31 December 2010. The performance of the Standard Life Healthcare book since acquisition has exceeded expectations and indications are that the present value of the projected future after-tax shareholder cash flows of the business in-force at the valuation date will exceed the current valuation. The values for PruHealth and Standard Life Healthcare at 31 December 2010 reflect Discovery`s 75% shareholding at that date (values for PruHealth in prior periods reflect Discovery`s 50% shareholding). The auditors, PricewaterhouseCoopers Inc., have reviewed the consolidated value of in-force business and value of new business of Discovery Holdings Limited and its subsidiaries as included in the embedded value statement for the six months ended 31 December 2010. A copy of the auditors` unqualified report is available for inspection at the company`s registered office. Table 1: Group embedded value R million 31 31 % Change 30 June December December 2010 2010 2009 Shareholders` funds 9 168 7 808 17 8 382 Adjustment to (6 839) (4 398) (4 883) shareholders` funds from published basis(1) Adjusted net worth 2 329 3 410 (32) 3 499 - Free Surplus 1 153 2 418 2 440 - Required Capital(2) 1 176 992 1 059 Run-down costs for - (30) - Destiny Health Value of Standard Life 522 - - Healthcare in-force business acquired(3) Value of in-force 22 231 18 371 19 996 covered business before cost of capital Cost of required (375) (324) (351) capital Cost of STC(4) (633) (540) (586) Discovery Holdings 24 074 20 887 15 22 558 embedded value Number of shares 555.0 554.3 553.9 (millions) Embedded value per R43.37 R37.68 15 R40.72 share Diluted number of 591.2 591.3 591.3 shares (millions) Diluted embedded value R42.99 R37.37 15 R40.31 per share(5) (1) The published Shareholders` funds has been adjusted to eliminate net assets under insurance contracts, deferred tax and deferred acquisition costs at December 2010 of R5 466 million (June 2010: R4 858 million; December 2009: R4 374 million) in respect of Life and R39 million (June 2010: R25 million; December 2009: R24 million) in respect of PruHealth. The December 2010 adjustment also includes R1 334 million of Discovery`s share of goodwill and intangible assets (net of deferred tax) relating to the acquisition of Standard Life Healthcare and the Prudential joint venture. (2) The required capital at December 2010 for Life is R606 million (June 2010: R550 million; December 2009: R516 million), for Health and Vitality is R407 million (June 2010: R395 million; December 2009: R367 million) and for PruHealth is R163 million (June 2009: R114 million; December 2009: R109 million). For Life, the required capital was set equal to two times the statutory Capital Adequacy Requirement ("CAR"). For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. For PruHealth, the long-term required capital amount has increased from 18% to 19.8% of annualised premium income. Allowance has also been made for additional capital required over the next 24 months. (3) Discovery`s share of the value of the Standard Life Healthcare in-force business has been calculated based on the acquisition price of GBP138 million less the net asset value of the business at 31 December 2010. (4) In line with Discovery`s current dividend policy, the cost of STC is calculated assuming a 4.5 times dividend cover on the after-tax profits as they emerge over the projection term. An STC rate of 10% is assumed. The total STC charge has been allocated between the different business entities based on their contribution to the total value of in-force covered business. (5) The diluted embedded value per share allows for Discovery`s BEE transaction where the impact is dilutive ie where the current embedded value per share exceeds the current transaction value. Table 2: Value of in-force covered business R million Value Cost of Cost of Value before required STC after cost of capital cost of
capital capital and STC and STC at 31 December 2010 Health and Vitality 10 840 (144) (307) 10 389 Life and Invest(1) 11 006 (168) (315) 10 523 PruHealth(2) 385 (63) (11) 311 Total 22 231 (375) (633) 21 223 at 31 December 2009 Health and Vitality 8 697 (129) (255) 8 313 Life and Invest(1) 9 409 (163) (277) 8 969 PruHealth(2) 265 (32) (8) 225 Total 18 371 (324) (540) 17 507 at 30 June 2010 Health and Vitality 9 896 (145) (289) 9 462 Life and Invest(1) 9 902 (174) (291) 9 437 PruHealth(2) 198 (32) (6) 160 Total 19 996 (351) (586) 19 059 (1) Included in the Life and Invest value of in-force covered business is R278 million (June 2010: R226 million; December 2009: R153 million) in respect of investment management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth. (2) The PruHealth value of in-force has been converted using the closing exchange rate of R10.30/GBP (June 2010: R11.48/GBP; December 2009: R11.90/GBP). The values for PruHealth at 31 December 2010 reflect Discovery`s 75% shareholding at that date (values in prior periods reflect Discovery`s 50% shareholding). Table 3: Group embedded value earnings Six months Six months Year ended ended ended R million 31 December 31 December 30 June 2010 2009 2010
Embedded value at end of period 24 074 20 887 22 558 Less: Embedded value at (22 558) (20 040) (20 040) beginning of period Increase in embedded value 1 516 847 2 518 Net increase in capital (17) (5) 7 Dividends paid 214 194 375 Shares issued to non- - (2) (2) controlling interests Transfer to hedging reserve 10 18 (12) Embedded value earnings 1 723 1 052 2 886 Annualised return on opening 15.9% 10.8% 14.4% embedded value Table 4: Components of Group embedded value earnings R million Net worth Cost of Value of Embedded required in-force value capital covered
business less cost of STC
Total profit from new (991) (29) 1 701 681 business (at point of sale) Profit from existing business - Expected return 915 (1) 129 1 043 - Change in methodology 323 13 (103) 233 and assumptions(1) - Experience variances (17) 4 383 370 Acquisition of Standard (751) (19) 616 (154) Life Healthcare and Prudential joint venture(2) Other initiative costs(3) (104) - 8 (96) Non-recurring expenses(4) (63) - 1 (62) Acquisition costs(5) (28) - (0) (28) Foreign exchange rate (355) 7 (37) (385) movements Cost of STC (21) - 13 (8) Return on shareholders` 129 - - 129 funds(6) Embedded value earnings (963) (25) 2 711 1 723 (1) The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and economic environment. The current period`s changes are described in detail in Table 5 below (for previous periods refer to previous embedded value statements). (2) Whilst the acquisition of Standard Life Healthcare is embedded value neutral, an embedded value loss arises on the increase in Discovery`s shareholding in the Prudential joint venture as the embedded value places no value on the right to use the Prudential brand, the right to use the Prudential balance sheet or on Discovery`s increased share of the value of in- force PruProtect business. (3) This item reflects the expenses relating to the acquisition of Standard Life Healthcare, the investment in Ping An Health, the establishment of The Vitality Group in the United States, PruProtect and Discovery Invest. These costs have not been projected on a recurring basis in the embedded value due to the fact that income from business sold under these initiatives has not been projected or the costs are not expected to recur. (4) Non-recurring expenses include Group costs related to one-off marketing events and one-off remuneration costs payable on the relocation of senior executives. (5) Acquisition costs relate to commission paid on Life business and expenses incurred in writing Health and Vitality business that has been written over the period but that will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the costs are excluded. (6) Return on shareholders` funds is shown net of tax and management charges. Table 5: Methodology and assumption changes Health and Life and PruHealth
Vitality Invest R million Net Value Net Value Net Value Total worth of worth of worth of in- in- in-
force force force Modelling - - 204 (283) - (8) (87) changes(1) Expenses - 487 1 10 - - 498 Lapses and - - 5 (32) - (64) (91) surrenders Mortality and - - (9) 7 - - (2) morbidity Benefit - - (41) 11 - - (30) enhancements Commission - - - - - (20) (20) Vitality - (84) - - - - (84) Economic - (11) (7) 165 - (6) 141 assumptions Premium and - - 2 (1) - - 1 benefit increases Increased - - - - - (11) (11) capital requirement Reinsurance(2 - - 337 (352) (169) 102 (82) ) Total - 392 492 (475) (169) (7) 233 (1) The Life and Invest modelling changes relate mainly to a change in the statutory reserving methodology for Invest policies and to the modelling of waiver of premium claims. (2) The reinsurance item relates to the impact of the financing reinsurance arrangements Table 6: Experience variances Health and Life and PruHealth Vitality Invest R million Net Value Net Value Net Value Total worth of worth of worth of in- in- in- force force force Renewal 21 - (1) 0 16 (7) 29 expenses Lapses and 6 183 15 106 - - 310 surrenders(1) Mortality and - - 41 (2) 33 (8) 64 morbidity Policy - (11) (97) 56 - - (52) alterations(2 ) Backdated - - (27) 7 - - (20) cancellations Premium - - 2 (10) - - (8) income Economic 0 28 (17) (13) - - (2) assumptions(3 ) Tax(4) (12) - 94 (90) (30) 2 (36) Reinsurance - - 28 (10) (13) - 5 Extended - 97 - 4 - 14 115 modelling term Other (2) (6) (35) 40 (39) 7 (35) Total 13 291 3 88 (33) 8 370 (1) The total Health and Vitality lapse experience variance of R189 million consists of a positive variance of R92 million due to lower than expected lapses and a positive variance of R97 million due to the net growth in existing employer groups (i.e. R420 million in respect of members joining existing employer groups during the period offset by an amount of R323 million in respect of members leaving existing employer groups). (2) Policy alterations relate to changes to existing benefits at the request of the policyholder. (3) For Life and Invest, the economic assumptions variance relates primarily to lower than expected premium and benefit increases due to lower than expected inflation over the period. (4) The tax variance for Life and Invest arises due to a movement in the deferred tax asset which delays the payment of tax. Table 7: Embedded value of new business R million Six Six % change Year months months ended ended ended 30 June 31 31 2010
December December 2010 2009 Health and Vitality Present value of future 223 164 541 profits from new business at point of sale Cost of required capital (7) (6) (18) Cost of STC (6) (10) (16) Present value of future 210 148 42 507 profits from new business at point of sale after cost of required capital and STC New business annualised 713 576 24 2 254 premium income(1) Life and Invest Present value of future 498 478 879 profits from new business at point of sale(2) Cost of required capital (17) (17) (33) Cost of STC (14) (14) (26) Present value of future 467 447 4 820 profits from new business at point of sale after cost of required capital and STC New business annualised 883 804 10 1 621 premium income(3) Annualised profit margin(4) 6.4% 6.5% 5.9% Annualised profit margin 9.0% 9.0% 8.4% excluding Invest Business PruHealth Present value of future 9 22 16 profits from new business at point of sale Cost of required capital (5) (3) (6) Cost of STC (0) (1) (0) Present value of future 4 18 (78) 10 profits from new business at point of sale after cost of required capital and STC New business annualised 109 60 82 147 premium income(5) Annualised profit margin(4) 0.6% 3.3% 0.7% (1) Health new business annualised premium income is the gross contribution to the medical schemes. For embedded value purposes, Health new business is defined as individuals and members of new employer groups, and includes additions to first year business. There have been no changes to the definition of new business since the previous valuation. The new business annualised premium income shown above excludes premiums in respect of members who join an existing employer after the first year, as well as premiums in respect of new business written during the period but only activated after 31 December 2010. The total Health and Vitality new business annualised premium income written over the period was R2 061 million (June 2010: R4 679 million; December 2009: R1 862 million). (2) Included in the Life and Invest value of new business is R1 million (June 2010: R22 million; December 2009: R5 million) in respect of investment management services provided on off balance sheet investment business. (3) Life new business is defined as Life policies or Discovery retirement Optimiser policies which incepted during the reporting period and which are on risk at the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. The new business annualised premium income of R883 million (June 2010: R1 621 million; December 2009: R804 million) (single premium APE: R224 million (June 2010: R480 million; December 2009: R210 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total Life new business annualised premium income written over the period, including both automatic premium increases of R195 million (June 2010: R392 million; December 2009: R196 million) and servicing increases of R151 million (June 2010: R290 million; December 2009: R116 million) was R1 229 million (June 2010: R2 303 million; December 2009: R1 116 million) (single premium APE: R224 million (June 2010: R480 million; December 2009: R210 million)). Single premium business is included at 10% of the value of the single premium. Policy alterations, including Discovery retirement Optimisers added to existing Life Plans are shown in Table 6 as experience variances and not included as new business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been recognised in the value of new business. Term extensions on existing contracts are not included as new business. (4) The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums (5) PruHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month as well as premiums in respect of new business written during the period but only activated after 31 December 2010. There have been no changes to the definition of new business since the previous valuation. Table 8: Embedded value economic assumptions 31 December 31 December 30 June 2010 2009 2010 Beta coefficient South Africa 0.56 0.51 0.54 United Kingdom 0.56 0.51 0.54 Equity risk premium South Africa 3.50 3.50 3.50 United Kingdom 4.00 4.00 4.00 Risk discount rate (%) -'Health and Vitality 10.46 10.79 10.89 -'Life and Invest 10.46 10.79 10.89 -'PruHealth 6.73 6.99 6.62 Rand / GB Pound Exchange Rate Closing 10.30 11.90 11.48 Average 11.04 12.43 11.96 Medical inflation (%) South Africa 7.50 8.00 8.00 United Kingdom 7.00 Current 7.00 levels reducing to
7.00% over the projection period
Expense inflation and CPI (%) South Africa 4.50 5.00 5.00 United Kingdom 3.75 3.75 3.75 Pre-tax investment return (%) South Africa 7.00 7.50 7.50 - Cash - Bonds 8.50 9.00 9.00 - Equity 12.00 12.50 12.50 United Kingdom 3.99 4.45 3.96 - Risk free Dividend cover ratio 4.5 times 4.5 times 4.5 times Income tax rate (%) South Africa 28.00 28.00 28.00 United Kingdom 28.00% 28.00 28.00% reducing reducing to to
24.00% in 24.00% April 2014 in April 2014
Projection term -'Health and Vitality 20 years 20 years 20 years -'Group Life 10 years 10 years 10 years -'PruHealth 20 years 20 years 20 years Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available, augmented by reinsurance and industry information. An additional lapse rate is assumed over the next 12 months to allow for the potential impact of the current economic climate on policyholder lapses. The Health lapse assumptions were based on the results of recent experience investigations. The lapse rate for the projection term after 10 years was set above current experience. The PruHealth assumptions were derived from internal experience augmented by industry information. Best estimate morbidity assumptions and forecast Vitality costs allow for the impact of management actions. The lapse rate over the short-term is assumed to be higher than the long-term expected lapse rate to allow for the impact of the current economic climate on lapses. Renewal expense assumptions were based on the results of the latest expense and budget information. The initial expenses included in the calculation of the value of new business are the actual costs incurred, except for Invest business where the initial expenses are based on medium-term expectations which are lower than the current total costs. This reflects a realistic position for Invest. The investment return assumption was based on a single interest rate derived from the risk-free zero coupon government bond yield curve. Other economic assumptions were set relative to this yield. The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the net investment return assumption. It is assumed that, for the purposes of calculating the cost of required capital, the Life required capital amount will be backed by surplus assets consisting of 100% equities and the Health, Vitality and PruHealth required capital amounts will be fully backed by cash. Allowance has been made for tax and investment expenses in the calculation of the cost of capital. In calculating the capital gains tax ("CGT") liability, it is assumed that the portfolio is realised every five years. The Life cost of capital is calculated using the difference between the gross of tax equity return and the equity return net of tax and expenses. The Health and PruHealth cost of capital is calculated using the difference between the risk discount rate and the net of tax cash return. Sensitivity to the embedded value assumptions The embedded value has been calculated in accordance with the Actuarial Society of South Africa`s Professional Guidance Note PGN 107: Embedded Value Reporting. The updated guidance note was applied for the first time in December 2008. The risk discount rate, calculated in accordance with the updated guidance note, uses the CAPM approach with specific reference to the Discovery beta coefficient. The Discovery beta coefficient reflects the historic performance of the Discovery share price relative to the market and infers a lower allowance for non-market related and non-financial risk. Previously, the potential cost of these risks to shareholders was allowed for through a higher margin in the risk discount rate. Investors may want to form their own view on an appropriate allowance for the non-financial risks which have not been modelled explicitly. The sensitivity of the embedded value and the value of new business at 31 December 2010 to changes in the risk discount rate is shown below. In determining the values at different risk discount rates, all other assumptions have been left unchanged. Table 9: Embedded value sensitivity to risk discount rate R million Risk discount Published risk Risk discount rate -1% discount rate rate +1% Adjusted net worth plus 2 851 2 851 2 851 value of Standard Life Healthcare Value of in-force covered 24 436 22 231 20 369 business before cost of capital Cost of required capital (379) (375) (370) Cost of STC (736) (633) (556) Discovery Holdings 26 172 24 074 22 294 embedded value Table 10: Value of new business sensitivity to risk discount rate R million Risk discount Published risk Risk discount rate -1% discount rate rate +1%
Present value of future 886 730 597 profits from new business at point of sale Cost of required capital (29) (29) (27) Cost of STC (27) (20) (16) Present value of future 830 681 554 profits from new business at point of sale after cost of required capital and STC Transfer secretaries Computershare Investor Services (Pty) Limited'(Registration number 2004/003647/07) Ground Floor, 70 Marshall Street, Johannesburg 2001'PO Box 61051, Marshalltown 2107 Sponsors Rand Merchant Bank (A division of FirstRand Bank Limited) Secretary and registered office MJ Botha, Discovery Holdings Limited (Incorporated in the Republic of South Africa) (Registration number: 1999/007789/06) JSE share code: DSY'ISIN: ZAE000022331 155 West Street, Sandton 2146 PO Box 786722, Sandton 2146 Tel: (011) 529 2888'Fax: (011) 529 2958 Directors MI Hilkowitz (Chairperson), A Gore* (Chief Executive Officer), Dr BA Brink, P Cooper, SB Epstein (USA), R Farber*, HD Kallner*, NS Koopowitz*, Dr TV Maphai, HP Mayers*, V Mufamadi, AL Owen (UK), A Pollard*, JM Robertson* (CIO), SE Sebotsa, T Slabbert, B Swartzberg*, SV Zilwa'*Executive Date: 22/02/2011 10:00:01 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Share This Story